• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,562.90 2,946.32
( 3.95%)
Global Indices
Nasdaq
46,614.19 -76.70
(-0.16%)
Dow Jones
6,639.23 6.40
(0.10%)
Hang Seng
56,345.93 2,916.37
(5.46%)
Nikkei 225
10,596.41 247.62
(2.39%)
Forex
USD-INR
92.93 0.25
(0.27%)
EUR-INR
107.23 0.49
(0.46%)
GBP-INR
122.94 0.71
(0.58%)
JPY-INR
0.58 0.00
(0.32%)

EQUITY - MARKET SCREENER

Bharat Forge Ltd
Industry :  Castings & Forgings
BSE Code
ISIN Demat
Book Value()
500493
INE465A01025
231.3231696
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
BHARATFORG
59.76
79881.44
EPS(TTM)
Face Value()
Div & Yield %
27.96
2
0.51
 

Aurobindo Pharma receives USFDA approval for Dapagliflozin and Metformin Hydrochloride XR Tablets
Apr 07,2026
Aurobindo Pharma announced that the final approval is received from the US Food & Drug Administration (USFDA) to manufacture and market Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/ 500 mg, 5 mg/1000 mg, 10 mg/500 mg, and 10 mg/1000 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xigduo XR Tablets, 5 mg/ 500 mg, 5 mg/1000 mg, 10 mg/500 mg, and 10 mg/1000 mg, of AstraZeneca AB. These products will be manufactured at Unit-IV of APL Healthcare, a wholly owned subsidiary of the Company and will be launched immediately.